Pharming Group NV - Company Profile

Powered by

All the data and insights you need on Pharming Group NV in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Pharming Group NV Strategy Report

  • Understand Pharming Group NV position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Pharming Group NV: Overview

Select Item

Related keylists

Pharming Group NV (Pharming) develops precision medicines and innovative protein replacement therapies for the treatment of rare diseases and unmet medical needs. The company’s marketed product includes, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of acute hereditary angioedema (HAE) and has been approved in the US, the UK, Europe, Israel, and South Korea. Its product pipeline consists of leniolisib for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); α-Glucosidase for the treatment of Pompe disease. The company markets its products through own sales force and network of distributors and partners. Pharming is headquartered in Leiden, the Netherlands.

 Gain a 360-degree view of Pharming Group NV and make more informed decisions for your business Gain a 360-degree view of Pharming Group NV and make more informed decisions for your business Find out more
Headquarters Netherlands
Address Darwinweg 24, Leiden, 2333CR
Website www.pharming.com
Telephone 31 71 5247400
No of Employees 415
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange PHARM (AMS)
Revenue (2022) $245.3M 19.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -177.1% (2022 vs 2021)
Market Cap* $649.2M
Net Profit Margin (2022) XYZ -164.7% (2022 vs 2021)
* As of and is in US$
View Pharming Group NV financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Pharming Group NV premium industry data and analytics

40+

Clinical Trials

Determine Pharming Group NV go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Pharming Group NV’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate Pharming Group NV’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

12+

Pipeline Drugs

Identify which of Pharming Group NV’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Sales & Consensus Forecasts

Understand the current and future drug revenue for Pharming Group NV and assess market opportunity for new entrants with patient population 8-year forecasts.

2

Marketed Drugs

Understand Pharming Group NV’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Pharming Group NV’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Ruconest- Acute Hereditary Angioedema (HAE) Ruconest
Joenja- APDS Joenja
Pipeline
XYZ
XYZ
XYZ
Understand Pharming Group NV portfolio and identify potential areas for collaboration Understand Pharming Group NV portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Plans/Strategy In December, the company announced its plans to develop leniolisib for additional primary immunodeficiencies.
2023 Contracts/Agreements In June, the company entered into a definitive agreement with Novartis Pharma to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million.
2023 Regulatory Approval In March, the company secured an approval from the US Food and Drug Administration for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Pharming Group NV Takeda Pharmaceutical Co Ltd BioMarin Pharmaceutical Inc Argenx SE BioCryst Pharmaceuticals Inc
Headquarters Netherlands Japan United States of America Netherlands United States of America
City Leiden Chuo-Ku Novato Amsterdam Durham
State/Province - Tokyo California Noord-Holland North Carolina
No. of Employees 415 49,095 3,401 1,148 536
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Richard Peters Chairman Executive Board 2023 -
Sijmen De Vries, M.D. Chief Executive Officer; Director Executive Board - 63
Jeroen Wakkerman Chief Financial Officer Senior Management 2020 53
Mireille Sanders Chief Operating Officer Senior Management 2020 54
Daniela Dos Anjos Hanova Chief People Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Pharming Group NV key executives to enhance your sales strategy Gain insight into Pharming Group NV key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward